Eli Lilly and Company (NYSE:LLY) Trading 1.4% Higher – Here’s Why

Eli Lilly and Company (NYSE:LLY) shares shot up 1.4% on Friday . The stock traded as high as $1,066.65 and last traded at $1,058.05. 4,113,074 shares traded hands during trading, an increase of 1% from the average session volume of 4,066,637 shares. The stock had previously closed at $1,043.29.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Monday, November 10th. Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. CICC Research raised their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Stock Up 1.4%

The stock has a market cap of $1.00 trillion, a P/E ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm’s fifty day moving average is $849.83 and its 200 day moving average is $786.02.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently modified their holdings of LLY. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the last quarter. Bridgewater Advisors Inc. lifted its stake in shares of Eli Lilly and Company by 0.3% in the third quarter. Bridgewater Advisors Inc. now owns 3,955 shares of the company’s stock valued at $3,018,000 after buying an additional 11 shares during the period. Manske Wealth Management grew its position in Eli Lilly and Company by 2.5% during the third quarter. Manske Wealth Management now owns 448 shares of the company’s stock worth $342,000 after buying an additional 11 shares in the last quarter. Guardian Partners Inc. grew its position in Eli Lilly and Company by 0.3% during the third quarter. Guardian Partners Inc. now owns 4,000 shares of the company’s stock worth $3,302,000 after buying an additional 12 shares in the last quarter. Finally, FSA Wealth Management LLC increased its stake in Eli Lilly and Company by 4.0% during the third quarter. FSA Wealth Management LLC now owns 309 shares of the company’s stock valued at $236,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.